Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01943110 · ClinicalTrials.gov registry record · NA

Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.

A NA study, sponsored by PATH.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT01943110: Completed NA study, sponsored by PATH.

NCT01943110 is a NA study that has completed, run by PATH. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01943110, a NA study, has completed, sponsored by PATH.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate whether two intradermal (ID) vaccine delivery devices can safely and precisely inject liquid into the intradermal layer of the skin in three different injection locations

Primary Outcome

The proportion of saline injections resulting in delivery to the intradermal layer of the skin will be assessed by measurement of intradermal wheals with diameters ≥ 5mm and the volume of liquid injected.

Interventions

  • DEVICE ID adapter (autodisable)
  • DEVICE ID adapter (side load)

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2013-07
Est. Completion 2013-07
Phase NA
PATH

18 total trials

What the finished NCT01943110 record still lists

NCT01943110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which ID adapter (autodisable) is the first listed.

NCT01943110 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01943110 about?

NCT01943110 is a clinical study titled "Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.". The purpose of this study is to evaluate whether two intradermal (ID) vaccine delivery devices can safely and precisely inject liquid into the intradermal layer of the skin in three different injection locations

What is the current status of trial NCT01943110?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2013-07. Estimated completion is 2013-07.

What interventions are being tested in trial NCT01943110?

The interventions under investigation include: ID adapter (autodisable) (DEVICE), ID adapter (side load) (DEVICE).

Who is sponsoring clinical trial NCT01943110?

This trial is sponsored by PATH, which has 18 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01943110's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01943110, the US trial registry maintained by the National Library of Medicine. NCT01943110 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.